Heidelberg Pharma sees promising results in multiple myeloma trial
6th November 2025 Uncategorised 0
Lead ATAC candidate HDP-101 shows strong clinical activity and safety in phase 8 cohort

More: Heidelberg Pharma sees promising results in multiple myeloma trial
Source: News
